University of Oxford
-
NAFDAC partners with University of Oxford in US$5 M Initiative to guard Nigeria’s vaccine supply
The partnership will support Nigeria’s post-marketing vaccine surveillance system by evaluating innovative screening devices and expanding routine laboratory testing for vaccine lots.
-
Oxford begins human trials for the experimental Bundibugyo Ebola vaccine
The experimental vaccine was developed by scientists at the University of Oxford using the same vaccine technology employed in the Oxford-AstraZeneca COVID-19 vaccine.
-
Oxford launches first human trial of Bundibugyo Ebola vaccine as DRC outbreak intensifies
The BD-Ebov trial, which is being conducted in Oxford, will evaluate the safety, tolerability and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged between 18 and 55 years.
-
CEPI pledges US$60M to fast-track Bundibugyo Ebola vaccines from Moderna, Oxford, and IAVI
The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).